CinCor Pharma

In the first installment of our CEO Spotlight series we spoke with @cincorpharma's Marc de Garidel — whose photograph graces the "Wall of Fame" in our Paris headquarters — on his experience launching drugs and building global teams ⭐ hubs.ly/Q017Xfm20 #biotech #vc #sofi72

@Dobrenkz #

CinCor is pleased to announce it will join the Russell 2000® and Russell 3000® Indexes as part of the quarterly #IPO additions. bit.ly/36qBy6I

CinCor will host its fourth quarter & full year 2021 financial results call and webcast at 8:30am ET on Tuesday, March 22nd.   bit.ly/37C0PM1

We’d like to welcome June Lee, MD, to the company’s Board of Directors.  Dr. Lee brings decades of leadership experience in the biotechnology industry.   Read More: bit.ly/3ql9tFA

👋 Meet @cincorpharma, the newest @Nasdaq family member! $CINC is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, a small molecule inhibitor of aldosterone synthase for treating hypertension & other cardio-renal diseases.

.@cincorpharma is developing the next generation of treatments for cardiovascular diseases. 🔬 $CINC is working to improve the lives of patients suffering from chronic cardio-renal conditions. #NasdaqListed

Today CinCor is announcing pricing of initial IPO common stock.  Common stock expected to begin trading under the symbol CINC.   Read more: bit.ly/3G8o6kZ   #hypertension #PrimaryAldosteronism #CKD #CinCor

Please welcome Terry Coelho as Executive Vice President, Chief Financial Officer and Chief Business Development Officer. With her proven financial leadership in public and private biopharma, Terry will drive our business development and growth. Read more: bit.ly/3jKTm0k

We’d like to welcome Mason W. Freeman, M.D., as our new Executive VP, Clinical Development. A physician and researcher with expertise in lipid metabolism and cardiovascular disease, he will lead development of CIN-107 for multiple indications. Read more: bit.ly/3aRtOcZ

We have closed our $143 million Series B financing. Proceeds will support the ongoing clinical development of CIN-107 for treatment of #hypertension, #PrimaryAldosteronism and chronic kidney disease. Read more: bit.ly/3jeocyj #CKD

A warm welcome to our new CEO Marc de Garidel. We look forward to Marc’s leadership on our executive team and his continued presence on our Board of Directors. Read more: bit.ly/3ynGulu